USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
QUALITY BIOLOGICAL, INC.
Address:
QUALITY BIOLOGICAL, INC.
7581 LINDBERGH DRIVE
GAITHERSBURG, MD 20879
EIN:
521288264
DUNS:
103926911
Number of Employees:
25
Woman-Owned?:
Yes
Minority-Owned?:
Yes
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $990,650.00 16
SBIR Phase II $5,660,721.00 10

Award List:

SERUM-FREE MEDIUM FOR HEMATOPOIETIC CELLS

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$49,000.00
Agency:
HHS
Principal Investigator:
Ronald l brown
Abstract:
The long-term objective of this proposal is to develop a serum-free medium that will support the growth and differentiation of hematopoietic cells. the initial research will focus on the development of a serum-free medium that will support the growth and differentiation of erythrocytes,… More

SERUM-FREE MEDIUM FOR LAK AND NATURAL KILLER CELLS AND MONOCYTES

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The long range goal of the proposed research is to develop serum-free media formulations for the culture of human leukocytes in vitro. the objective of phase i studies is todevelop serum-free medium that would allow maximum growth and cytotoxic activity of non-mitogen activated human lymphokine… More

SERUM-FREE MEDIUM FOR THE CULTURE OF HUMAN HEMATOPOIETIC CELLS

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$49,453.00
Agency:
HHS
Principal Investigator:
Ronald L Brown
Abstract:
N/a

SERUM-FREE MEDIUM FOR THE CULTURE OF HUMAN HEMATOPOIETIC CELLS

Award Year / Program / Phase:
1991 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Ronald L Brown
Abstract:
The objectives of this project are to develop a standard serum-free medium that will support the proliferation and differentiation of human bone marrow stem cells in both short-term and long-term cultures. the research will focus on the development of a serum-free formulation to support this… More

Endothelial Cell Proliferation in Serum-Free Medium

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Ronald L. Brown
Abstract:
A precisely defined serum-free medium would be of inestimable importance for gaining specific information concerning phenom such as the proliferation of endothelial cells and the role these cells play in the process such as cardiovascular disease, wound healing and responsiveness to growth factors… More

Iron-Defined Serum-Free Medium

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Ronald L. Brown
Abstract:
N/a

Critical Reagents that Support Fetal Hematopoiesis

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Ronald L. Brown
Abstract:
N/a

Reagents for Vector Production for Hematopoietic Gene TX

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$81,000.00
Agency:
HHS
Principal Investigator:
Ronald Brown
Abstract:
The goal of this research is to develop critical reagents that will support the production of highvector titers for transfusion medicine, ie. hematopoietic gene therapy for treatment of blood disordersas well as other applications. Attempts at concentrating these vectors has generally resulted in… More

Reagents for Drug Toxicity Studies Using Megakaryocytes

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$80,998.00
Agency:
HHS
Principal Investigator:
Ronald Brown
Abstract:
The development of hematopoietic defined protein-free reagents that support megakaryocyteformation will be of inestimatable importance. The rationale for developing such reagents is that it willallow the measurement of drug toxicity in its unbound state in which all of the drug is active.… More

Critical Reagents that Support Fetal Hematopoiesis

Award Year / Program / Phase:
1994 / SBIR / Phase II
Award Amount:
$520,000.00
Agency:
HHS
Principal Investigator:
Ronald L. Brown
Abstract:
The overall goal is to develop serum-free medium for the proliferation and differentiation of fetal liver, spleen and bone marrow. The culture system will be comprised of serum-free medium and various cytokines. Serum-free medium will allow the direct effect the cytokines have on the fetal… More

Generating Cloned Attenuated Dengue 1 Viral cDNA Sequences

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$98,059.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
Sandra K. Dusing
Abstract:
N/a

Hematopoietic Kits for Osteoclast Formation

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
Ronald Brown
Abstract:
N/a

Iron-Defined Serum-Free Medium

Award Year / Program / Phase:
1995 / SBIR / Phase II
Award Amount:
$551,339.00
Agency:
HHS
Principal Investigator:
Ronald L. Brown
Abstract:
The importance of elucidating the mechanism(s) involved in iron metabolism is of great significance. The pathophysiological significance of oxygen free radicals and transition metal catalysis extends to any organ system and includes carcinogenesis including leukemia, coronary artery disease,… More

Generating Cloned Attenuated Dengue 1 Viral cDNA Sequences

Award Year / Program / Phase:
1995 / SBIR / Phase II
Award Amount:
$750,000.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
Sandra K. Dusing
Abstract:
Wild type (wt) dengue 1 viral RNA will be used as substrate to generate a complementary DNA (cDNA) library of clones that contain identified and sequenced DNA segments spanning the entire dengue 1 genome. Point mutations designed to generate amino acid alterations will be introduced at the… More

Hematopoietic Kits for Osteoclast Formation

Award Year / Program / Phase:
1995 / SBIR / Phase II
Award Amount:
$452,684.00
Agency:
HHS
Principal Investigator:
Ronald Brown
Abstract:
With the recent isolation and identification of osteoclast progenitors and the isolation andpurification of osteoclast colony stimulating factor, new and exciting avenues of research can now beapproached. The development of chemically defined osteoclast hematopoietic reagents would be ofinestimable… More

Development of Reagents for Stem Cell Differentiation

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
Ronald Brown
Abstract:
We will develop chemically defined reagents that support hematopoietic stem cell proliferation andSuch reagents would be valuable in hematological research especially for bone marrow transplantationex-vivo purging. Preliminary evidence indicates that it is feasible to replace the ill-defined and… More

Clinical Reagents for Peripheral Blood Stem Cells

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$74,997.00
Agency:
HHS
Principal Investigator:
Ronald Brown
Abstract:
N/a

Clinical Reagents for Peripheral Blood Stem Cells

Award Year / Program / Phase:
1997 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
Ronald Brown
Abstract:
We will develop fully defined, serum-free culture reagents, which contain no components of non- humwhich can be produced under completely controlled and reproducible pharmaceutical standards, and whiwith recombinant human hematopoietic factors will successfully support the generation and… More

DEVELOPMENT OF REAGENTS FOR STEM CELL DIFFERENTIATION

Award Year / Program / Phase:
1998 / SBIR / Phase II
Award Amount:
$749,999.00
Agency:
HHS
Principal Investigator:
Ronald Brown
Abstract:
We will develop chemically defined reagents that support hematopoietic stem cell proliferation andSuch reagents would be valuable in hematological research especially for bone marrow transplantationex-vivo purging. Preliminary evidence indicates that it is feasible to replace the ill-defined and… More

NOVEL MEGAKARYOCYTE REAGENTS

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Ronald L. Brown
Abstract:
Not Available Soldiers in tomorrow's Army will need new skills to function in a technology intensive environment. To assess potential performance in jobs of the future, we propose to develop a Job Skills Model that combines extensive existing models and performance data for today, s jobs with… More

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Ronald L. Brown
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Ronald L. Brown
Abstract:
N/a

MEGAKARYOCYTE REAGENTS SPECIFIC FOR THEIR MATURATION

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Ronald L. Brown
Abstract:
N/a

MEGAKARYOCYTE REAGENTS SPECIFIC FOR THEIR MATURATION

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$467,784.00
Agency:
HHS
Principal Investigator:
Ronald L. Brown
Abstract:
N/a

Ex Vivo Culture of Umbilical Cord Blood Stem Cells for Adult Transplantation

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$107,143.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this proposal is to delineate the ex vivo serum-free culture conditions to expand CD34+ cells derived from cryopreserved umbilical cord blood cells to levels that will support its use in the adult tr ansplant setting. The disadvantage of… More

Ex Vivo Culture of Umbilical Cord Blood Stem Cells for Adult Transplantation

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$818,915.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this proposal is to delineate the ex vivo serum-free culture conditions to expand CD34+ cells derived from cryopreserved umbilical cord blood cells to levels that will support its use in the adult tr ansplant setting. The disadvantage of… More